Product
Olutasidenib
Aliases
Olutasidenib + TMZ
Name
REZLIDHIA
INN Name
olutasidenib
FDA Approved
Yes
1 clinical trial
1 organization
20 indications
1 document
Indication
High-Grade GliomaIndication
AstrocytomaIndication
Grade IIIIndication
Grade IVIndication
Diffuse Intrinsic Pontine GliomaIndication
Anaplastic AstrocytomaIndication
GlioblastomaIndication
Metastatic Brain TumorIndication
Diffuse Midline GliomaIndication
H3 K27M-MutantIndication
Thalamic TumorIndication
Spinal TumorIndication
IDH1 MutationIndication
IDH1 R132Indication
IDH1 R132CIndication
IDH1 R132HIndication
IDH1 R132SIndication
IDH1 R132GIndication
IDH1 R132LIndication
OligodendrogliomaClinical trial
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 MutationsStatus: Not yet recruiting, Estimated PCD: 2029-06-01
Document
DailyMed Label: REZLIDHIAOrganization
Rigel Pharmaceuticals, Inc.